ood morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating because — you guessed it — the unrelenting routine of meetings, deadlines, and what-not has returned. You knew this would happen, yes? Well, what can you do except fire up the coffee kettle and quaff some cups of stimulation. Cinnamon coffee roll is our flavor today, for those who track this sort of thing. Meanwhile, here are some tidbits. Hope you have a smashing day and keep us in mind if you hear anything interesting …

Novartis increased pressure on Roche’s aging roster of big-selling drugs by becoming the latest company to win European approval for a lower-price version of the Rituxan drug, Reuters tells us. The drug, which is used to treat blood cancer and immunological diseases and is also known as MabThera, racked up $7.5 billion in global sales in 2016 and costs tens of thousands per year.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy